The focus of my efforts in the Structural and Biophysical Chemistry Group is early stage hit finding and hit validation for antiviral, antibacterial, and anticancer agents. We routinely employ biophysical methods (e.g., SPR, DSF, ITC) to enable project teams and to discover hits against key viral proteins by a variety of methods, including fragment-based screening and drug design, high-throughput screening, and the rational design of inhibitors. Our goal is to deliver well-validated molecules to the crystallographers to determine the structure of the molecule in the protein’s active site. We also perform mechanistic studies to probe protein-protein interactions that support hypotheses for a given anti-viral mechanism. We are constantly looking for novel technologies to gain unique insight into target-based drug discovery, and to improve our understanding of virology, with the ultimate goal of improving the lives of patients in need. Our current need is to expand our understanding of the biochemistry and cellular biology of BK virus (BKV), a polyomavirus, so that we can effectively stop the proliferation of the virus.